Home » Topics » Regulatory » EMA

EMA
RSS

Shire's VPRIV approved in Europe for type 1 Gaucher's disease

Aug. 27, 2010

Bristol-Myers Squibb offers pipeline update for Q2 2010

Aug. 24, 2010

Amsterdam Molecular Therapeutics provides update on Glybera MAA

Aug. 23, 2010

EMA accepts Optimer Pharma's fidaxomicin MAA for review

Aug. 20, 2010

European Commission grants midostaurin orphan drug status in mastocytosis

Aug. 18, 2010

European Commission grants orphan designation to Vertex's cystic fibrosis candidate

Aug. 18, 2010

EMA validates CTI's expanded pediatric program for pixantrone in NHL

Aug. 16, 2010

Dexamethasone intravitreal implant receives E.U. orphan drug status for noninfectious uveitis

Aug. 16, 2010

MK-4827 receives E.U. orphan drug status in ovarian cancer

Aug. 16, 2010

European Commission grants orphan status to bosutinib in CML

Aug. 13, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 11, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...